Investigating the Regulation and Potential Role of Nonhypoxic Hypoxia Inducible Factor 1 (HIF 1) in Aromatase Inhibitor Resistant Breast Cancer

Abstract

This research aims to understand the factors and molecular mechanisms involved in drug-resistant breast cancer, specifically aromatase inhibitor resistant breast cancer. Although aromatase inhibitors (AIs; i.e., letrozole) have been shown to be highly effective in treating estrogen receptor positive (ER+) breast cancer, a significant percentage of patients either do not respond to AIs or become resistant to them. Previous studies suggest that resistance to AIs involves a switch from dependence on ER signaling to dependence on growth factor-mediated pathways, such as human epidermal growth factor receptor-2 (HER2). The mechanism by which HER2 is involved in AI resistance remains mostly unclear. It is, therefore, important to elucidate theHER2-mediated pathway that contributes to AI resistance, and to identify other relevant factors involved that can be used as biomarkers of AI resistance or targets for therapy.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Dec 01, 2015
Accession Number
AD1020548

Entities

People

  • Armina A. Kazi

Organizations

  • University of Maryland, Baltimore

Tags

DTIC Thesaurus Topics

  • Analysis Of Variance
  • Antineoplastic Agents
  • Biological Factors
  • Breast Cancer
  • Cell Line
  • Cell Physiological Processes
  • Cells
  • Drug Resistance
  • Enzyme Inhibitors
  • Gene Expression
  • Growth Factors
  • Medical Personnel
  • Neoplasms
  • Oncology
  • Proteins
  • Statistical Analysis
  • Stem Cells

Fields of Study

  • Biology

Readers

  • Breast cancer cell signaling and growth regulation.
  • Geospatial Intelligence and Artificial Intelligence Analytics
  • Oncology (Cancer Research).